Ortner Maria-Anna
Department for Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, Lausanne CH 1011, Switzerland.
Best Pract Res Clin Gastroenterol. 2004 Feb;18(1):147-54. doi: 10.1016/S1521-6918(03)00100-8.
Symptoms occur late in cholangiocarcinoma and therefore only about half of the patients at the time of diagnosis are candidates for curative surgery. In patients with advanced non-resectable cholangiocarcinoma palliative treatment options are limited. Until now, insertion of endoprostheses for the treatment of cholestasis has been the method of choice. However, tumour growth cannot be influenced and so that prognosis is dismal. Although radiotherapy and chemotherapy are frequently used, prospective, randomized trials showing an improvement in survival time are missing. Encouraging results from prospective, single-arm phase II trials and a randomized trial using photodynamic therapy (PDT) in non-resectable cholangiocarcinoma indicate considerable benefit on survival with a good quality of life. Furthermore, PDT is well tolerated, with only few specific side-effects. This is of great importance in patients with short life expectancy. PDT should therefore be offered to all patients with non-resectable cholangiocarcinoma. However, before initiating PDT or any other palliative measure, a proper staging and a surgical consultation is necessary to avoid missing a curative surgical option.
胆管癌症状出现较晚,因此在诊断时只有约一半的患者适合进行根治性手术。对于晚期不可切除的胆管癌患者,姑息治疗选择有限。到目前为止,插入内支架治疗胆汁淤积一直是首选方法。然而,肿瘤生长无法得到控制,因此预后很差。尽管放疗和化疗经常使用,但缺乏显示生存时间改善的前瞻性随机试验。前瞻性单臂II期试验和一项在不可切除胆管癌中使用光动力疗法(PDT)的随机试验的令人鼓舞的结果表明,该疗法对生存有显著益处,且生活质量良好。此外,PDT耐受性良好,只有很少的特定副作用。这对于预期寿命较短的患者非常重要。因此,应向所有不可切除胆管癌患者提供PDT。然而,在开始PDT或任何其他姑息措施之前,进行适当的分期和外科会诊是必要的,以避免错过根治性手术选择。